Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Condition(s):Idiopathic Thrombocytopenic PurpuraLast Updated:September 11, 2019Withdrawn
Hide Studies Not Open or Pending
Condition(s):Idiopathic Thrombocytopenic PurpuraLast Updated:September 11, 2019Withdrawn
Condition(s):Birth Defect; Spontaneous Abortions; Low Birth WeightLast Updated:January 6, 2015Terminated
Condition(s):Idiopathic Thrombocytopenic PurpuraLast Updated:July 16, 2010Completed
Condition(s):Idiopathic Thrombocytopenic PurpuraLast Updated:March 6, 2024Enrolling by invitation
Condition(s):Immune Thrombocytopenia PurpuraLast Updated:May 16, 2023Recruiting
Condition(s):Adult Patients; Immune Primary Thrombocytopenia; Splenectomy; TPO-mimeticsLast Updated:October 14, 2020Completed
Condition(s):Thrombocytopenia; Drugs; Chronic Liver DiseaseLast Updated:November 15, 2022Recruiting
Condition(s):Immune ThrombocytopeniaLast Updated:October 23, 2018Unknown status
Condition(s):Primary Immune ThrombocytopeniaLast Updated:November 23, 2022Completed
Condition(s):Persistent or Chronic ITPLast Updated:February 18, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.